Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Cancer type

Prostate

Prostate cancer.

Must-know

  1. 1

    ctDNA in clinically localized prostate cancer

    Lau et al. Genome Medicine. 2020.

    ctDNA was uncommonly detected in clinically localized prostate cancer. A ctDNA TP53 mutation was associated with shorter metastasis-free survival (6.2 versus 9.5 years; hazard ratio 2.4, 95% CI 1.2–4.8).

    PMID 32807235DOI

A randomized ctDNA-guided prostate trial was not identified.

Listed when a study is a randomized or prospective interventional ctDNA or MRD trial, is cited in NCCN or ESMO guidance, or is a prospective validation cohort in a high-impact journal. Shorter lists mean fewer studies met that rule. No test is ranked.

Publications and presentations

Accruing studies for Prostate

Trials

GUProstateTier 2MRD / ctDNATrials

Circulating Tumor DNA in Oligoprogressive Prostate Cancer Treated With Stereotactic Radiotherapy: A Prespecified Secondary Analysis of a Nonrandomized Clinical Trial (TRAP)

JAMA Network Open published online on November 11, 2026 a prespecified secondary analysis of the nonrandomized phase 2 TRAP trial: plasma was tested with the previously validated prostate-directed PCF_SELECT panel before stereotactic body radiotherapy in men with metastatic castration-resistant prostate cancer and oligoprogression on abiraterone or enzalutamide. Of 77 evaluable patients (81 treated at 8 UK sites), 19 (24.7%) were ctDNA-positive. Six-month progression-free survival was 21.1% versus 58.3%, and median progression-free survival was 3.0 versus 7.8 months (log-rank P = .003; adjusted HR 2.18, 95% CI 1.21-3.94, P = .009). Median time to next therapy or death was 15.3 versus 29.6 months (adjusted HR 1.57, P = .20), and median overall survival was 27.2 versus 33.6 months (adjusted HR 2.24, P = .07). The trial was not randomized, so a prognostic association is not separated from a predictive one.

JAMA Network Open

GUProstateTier 2FDABiomarkers

FDA approves lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer

On July 31, 2026, the FDA approved lutetium Lu 177 vipivotide tetraxetan with an androgen-receptor pathway inhibitor for PSMA-positive metastatic androgen-pathway-naive or -sensitive prostate cancer, with patients selected using Locametz or another approved PSMA PET product; in PSMAddition (1,144 patients) radiographic progression-free survival HR was 0.72 and median radiographic progression-free survival was not reached in either arm.

U.S. FDA

GUProstateTier 2FDABiomarkers

FDA approves capivasertib plus abiraterone for PTEN-deficient metastatic hormone-sensitive prostate cancer

On June 12, 2026, the FDA approved capivasertib with abiraterone and prednisone for PTEN-deficient metastatic androgen-pathway-naive or -sensitive prostate cancer, and approved the VENTANA PTEN (SP218) RxDx Assay, which calls PTEN deficiency when at least 90% of viable malignant cells have no specific cytoplasmic staining; in CAPItello-281 (1,012 patients) median radiographic progression-free survival was 33.2 versus 25.7 months (HR 0.81), and overall survival was immature.

U.S. FDA

ASCO GU 2026: early ctDNA clearance in COMRADE tracked with longer rPFS in bone-dominant mCRPC

In a biomarker analysis of the phase 2 COMRADE trial presented at ASCO GU 2026, undetectable ctDNA at cycle 2 day 1 was associated with longer radiographic progression-free survival than detectable ctDNA (median 9.9 versus 2.7 months; HR 0.47) among 94 analyzed patients with bone-dominant metastatic castration-resistant prostate cancer.

UroToday